Power to Decide and Medicines360 Announce Partnership to Expand Access to Contraception
WASHINGTON, D.C. – Today, millions of women in need of contraception struggle with access to this basic part of women’s health care. To help women access this needed service, Power to Decide and Medicines360, a mission-driven nonprofit women’s health pharmaceutical, will partner to help expand access to contraception for all women. This partnership aims especially to help […]
Newly Published Data from Phase 3 Clinical Trial of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg Confirms Efficacy, Safety, and Tolerability Through Five Years
Data from ACCESS IUS, the largest ongoing Phase 3 clinical trial in the U.S. of an intrauterine system evaluating pregnancy prevention, also reports bleeding profile over five years in diverse women SAN FRANCISCO – Medicines360, a global nonprofit women’s health pharmaceutical company, announced newly published data finding that LILETTA is highly efficacious in preventing pregnancy over five […]
FDA Approves Medicines360’s sNDA for LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg to Prevent Pregnancy for up to Five Years
DUBLIN and SAN FRANCISCO – Allergan plc (NYSE: AGN), a leading global pharmaceutical company, and Medicines360, a global nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, announced that the U.S. Food and Drug Administration (FDA) approved Medicines360’s Supplemental New Drug Application (sNDA) to extend the duration of use of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg for […]
Medicines360, Afaxys Partner to Expand Public Health Access to LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg
Strategic alliance will increase engagement with U.S. public health clinics and their patients about hormonal IUDs (long-acting reversible contraceptives, or LARCs) SAN FRANCISCO and CHARLESTON, S.C. – Medicines360 and Afaxys Pharma, LLC, two mission-driven, socially conscious women’s health pharmaceutical companies, today announced their collaboration to promote Medicines360’s intrauterine system (IUS), LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg, which is […]
Medicines360 and Direct Relief Partner to Expand Access for U.S. Women
Partnership will provide free hormonal IUDs to underserved women across the country SAN FRANCISCO and SANTA BARBARA, Calif. – Medicines360, a mission-driven women’s health pharmaceutical nonprofit and Direct Relief, a humanitarian aid organization, today announced their partnership to provide Medicines360’s hormonal IUD, LILETTA®, free of charge to clinics that serve the most vulnerable women in the United States, […]
Medicines360 Expands Access To Contraception In Africa
FORBES – Medicines360, the non-profit pharmaceutical company behind the hormonal IUD Liletta, is on a mission to increase women’s access to reproductive care around the world. This month, the female-led company announced the launch of Avibela, a hormonal IUD, in Madagascar.
Medicines360, WCG, and Population Services International Announce Launch of AVIBELA™ Hormonal Intrauterine System in Madagascar
Approval Expands Contraceptive Access for Women in Madagascar SAN FRANCISCO and SAN DIEGO and WASHINGTON – Medicines360, WCG, and Population Services International (PSI) today announced the launch of AVIBELA (levonorgestrel-releasing intrauterine system) 52 mg in Madagascar. This is the first registration and launch of Medicines360’s hormonal intrauterine system (IUS or IUD) in Africa. AVIBELA’s introduction in Madagascar is supported by WCG’s Expanding Effective Contraceptive […]
Medicines360 and Allergan Present 5-Year Trial Data from Largest On-going IUS Clinical Study
Medicines360 and Allergan Present Five-Year Multi-Center Pivotal Clinical Trial Data of LILETTA® (levonorgestrel-releasing intrauterine system) 52 mg at 2018 ACOG Meeting SAN FRANCISCO and DUBLIN – Medicines360, a nonprofit women’s health pharmaceutical company with a mission of expanding access to quality medicines, and Allergan plc (NYSE: AGN), a leading global pharmaceutical company, presented five-year data from their ongoing multi-center U.S.-based […]
Jessica Grossman, M.D., CEO of Medicines360, Wants to Make Sure Women Have Reproductive Healthcare Choices
Jessica Grossman, M.D., CEO of Medicines360, wants to empower women when it comes to choices surrounding their reproductive healthcare.
How To Rechart Your Career Path, According To One M.D. Turned CEO
Jessica Grossman, M.D., is a fan of the calculated risk. Taking one to change careers after medical school landed her in a role that is helping shape the future of women’s healthcare.
